Q1 2025 · 13F-HR
Caligan Partners LPholdings as filed
Filed 2025-05-15 · accession 0001420506-25-001290
$479.2M
Reported value
16
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $119.7M | 25.0% | 8,118,592 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $91.2M | 19.0% | 1,436,878 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $56.3M | 11.8% | 1,525,730 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $34.1M | 7.12% | 2,149,667 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $32.9M | 6.86% | 2,731,154 | Common | SOLE |
| 78667J108 | SG7 | SAGE THERAPEUTICS INC | $24.3M | 5.06% | 3,052,538 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $23.3M | 4.86% | 3,107,669 | Common | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $21.6M | 4.50% | 1,435,130 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $20.5M | 4.29% | 701,280 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $16.4M | 3.43% | 465,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $15.9M | 3.31% | 376,954 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $10.4M | 2.17% | 2,342,609 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $7.9M | 1.66% | 1,269,119 | Common | SOLE |
| 92511W108 | — | VERRICA PHARMACEUTICALS INC | $4.0M | 0.83% | 8,992,954 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $409,796 | 0.09% | 141,309 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $232,500 | 0.05% | 25,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.